Cantabio Pharmaceuticals Inc.: 10-K filed 2017-06-30
What Cantabio Pharmaceuticals Inc. reported in its annual report filed 2017-06-30 (fiscal FY 2017): 16 published measures, 33 facts as tagged in accession 0001424884-17-000049.
This filing
- Form
- 10-K (annual report)
- Filed
- 2017-06-30
- Fiscal period
- fiscal FY 2017
- Accession
- 0001424884-17-000049 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cantabio Pharmaceuticals Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 33,523 | USD | |
| At 2016-03-31 | 52,110 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 887,445 | USD | |
| At 2016-03-31 | 421,894 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -853,922 | USD | |
| At 2016-03-31 | -369,784 | USD | |
| At 2015-03-31 | -218,456 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 32,275 | USD | |
| At 2016-03-31 | 52,110 | USD | |
| At 2015-03-31 | 209 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | -1,112,138 | USD | 365 |
| 2015-04-01 to 2016-03-31 | -751,328 | USD | 366 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | -973,120 | USD | 365 |
| 2015-04-01 to 2016-03-31 | -564,660 | USD | 366 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | 953,285 | USD | 365 |
| 2015-04-01 to 2016-03-31 | 616,561 | USD | 366 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -2,108,051 | USD | |
| At 2016-03-31 | -995,913 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 33,523 | USD | |
| At 2016-03-31 | 52,110 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | 39,869 | USD | 365 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 887,445 | USD | |
| At 2016-03-31 | 421,894 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | 350,310 | USD | 365 |
| 2015-04-01 to 2016-03-31 | 149,159 | USD | 366 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 26,805,270 | shares | |
| At 2016-03-31 | 26,805,270 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 167,324 | USD | |
| At 2016-03-31 | 99,324 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | 718,959 | USD | 365 |
| 2015-04-01 to 2016-03-31 | 691,778 | USD | 366 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2017-03-31 | -42,869 | USD | 365 |
| 2015-04-01 to 2016-03-31 | 89,609 | USD | 366 |
Inspect the source
- Entity
- Cantabio Pharmaceuticals Inc. / CIK 0001550518
- Captured
- SEC response SHA-256
26e01cc835263ee42b9e049928b950a5cdad11113c7a9790a0d459b7e7f1dd12
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001550518.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))